First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
Melbourne (Australia) and Istanbul (Turkey) – 22nd October 2020. Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical trial
Telix Pharmaceuticals and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Turkey.
The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth. Under a contract manufacturing agreement, Eczacıbaşı Monrol will supply 89Zr-labelled TLX250-CDx for the Turkish clinical sites.
The ZIRCON trial includes four participating clinical study sites in Turkey, comprising Istanbul Training and Research Hospital, Istanbul University-Cerrahpasa, Ankara Hacettepe University and Ankara University.
Telix Chief Medical Officer, Dr Colin Hayward stated, “We are pleased to have commenced the Phase III ZIRCON clinical trial in Turkey and wish to acknowledge the team at Eczacıbaşı Monrol, as well as the principal investigators and study teams at each of the four institutions participating in the study, who have made this important milestone possible.”
Aydın Küçük, General Manager of Eczacıbaşı Monrol added, “As one of our missions is to contribute to the human health, we are very honoured to be part of this significant achievement of the ZIRCON clinical trial initiation in Turkey with the first patients’ doses manufactured at our Istanbul facility, and we are thankful to the Telix team for this great collaboration.”
To read the full media release please click here.
TLX250-CDx does not have regulatory approval in any jurisdiction.
Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...
Telix Presentation at the European Multidisciplinary Congress on Urological Cancers
20th November 2020 | Corporate Spotlight | Recording of Live Presentation at EMUC20 Virtual Congress: New Perspectives in Prostate and...
Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe
Melbourne (Australia) and Liège (Belgium) – 19th November 2020. Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from...
Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium
13th November 2020 | Corporate Spotlight – Recording of live presentations at EANM Virtual Symposium: Next Generation Imaging with PSMA-PET...
Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership
Melbourne (Australia) – 3rd November 2020. Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
Melbourne (Australia) and Hong Kong SAR (China) – 2nd November 2020. Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic...
Activity Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 30th October 2020. Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020,...
Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting
28th October 2020 – Clinical Spotlight | Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting
Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery
Melbourne (Australia) and Heidelberg, (Germany) – 28th October 2020. Telix has secured an exclusive Intellectual Property licence agreement with the...
Completion of Phase I Enrolment of Japanese Renal Cancer Study
Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...